Living with CDKL5 deficiency disorder brings many challenges, but modern medicine offers ways to ease the burden. Understanding the available treatment approaches, from standard medications to emerging therapies being tested in clinical trials, helps families navigate this complex condition and make informed decisions about care.

Navigating the Treatment Landscape for CDKL5 Deficiency Disorder

When a child receives a diagnosis of CDKL5 deficiency disorder (sometimes called CDD), parents quickly learn that treatment focuses on managing symptoms rather than curing the condition itself. The primary goals involve reducing the frequency and severity of seizures, supporting development as much as possible, addressing feeding and sleep problems, and improving overall quality of life for both the child and their family.^[1][2]

Treatment approaches vary significantly from one child to another because CDKL5 deficiency disorder affects each person differently. The severity of symptoms, the specific type of genetic change in the CDKL5 gene, and how a child responds to various therapies all influence the treatment plan. Medical decisions depend heavily on the child’s age, the stage of their condition, which symptoms are most troubling, and how their body reacts to interventions tried so far.^[3]

Healthcare providers follow international consensus recommendations that outline best practices for assessing and managing individuals with CDD. Because this disorder affects multiple body systems—the brain, digestive system, muscles, vision, and more—children typically need care from a team of specialists working together. This might include neurologists, gastroenterologists, physical therapists, occupational therapists, dietitians, and others. Many families benefit from visiting a CDKL5 Center of Excellence, where coordinated, specialized care makes it easier to address the many facets of this complex condition.^[3][4]

Importantly, while standard treatments approved by medical societies exist for managing CDD symptoms, researchers are actively investigating new therapies. Clinical trials are testing promising medications specifically designed for this disorder, offering hope for more targeted and effective options in the future.^[4]

Standard Medical Treatments for CDKL5 Deficiency Disorder

Controlling Seizures: The Central Challenge

Seizures represent the most prominent and challenging feature of CDKL5 deficiency disorder. In most children, seizures begin within the first three months of life—sometimes as early as the first week after birth. These seizures are notoriously difficult to control, and the unfortunate reality is that they occur daily in most people with CDD, although some children experience periods when they are seizure-free.^[1][2]

The types of seizures children experience often change as they grow. Common types include generalized tonic-clonic seizures, which involve loss of consciousness, muscle rigidity, and convulsions; tonic seizures, characterized by abnormal muscle contractions; and epileptic spasms, which involve short episodes of muscle jerks. Some children have seizures with multiple distinct phases, such as the hypermotor-tonic-spasms sequence.^[1][2]

Because seizures in CDKL5 deficiency disorder usually do not respond well to treatment, doctors typically set a realistic goal: managing seizures rather than eliminating them completely. Healthcare providers commonly prescribe anti-seizure medications (also called anticonvulsants or antiepileptic drugs) to try to reduce how often seizures happen and make them less severe when they do occur.^[9]

In one study examining treatment patterns across 177 individuals with CDD, the four most frequently prescribed anti-seizure medications were all broad-spectrum drugs, used in over 50 percent of patients. However, the response to these medications varied considerably. Among those for whom treatment response data was available, only 14 to 48 percent achieved a two-week response to treatment, and just 5 to 36 percent maintained a sustained three-month response. This highlights the significant challenge that seizure control poses in CDKL5 deficiency disorder—no single medication emerged as clearly superior, and many children continued to have frequent seizures despite trying multiple drugs.^[9]

The Ketogenic Diet as a Therapeutic Tool

In addition to medications, about half of individuals with CDD are treated with the ketogenic diet, a specialized high-fat, low-carbohydrate eating plan that has been used for decades to help control seizures. The diet works by changing how the body produces energy, shifting from using glucose (sugar) to using ketones (produced from fat breakdown). This metabolic change can reduce seizure activity in some children, though the exact reason why remains incompletely understood.^[9]

The ketogenic diet requires careful supervision by a dietitian and medical team. Children following this diet need regular monitoring to ensure they receive adequate nutrition for growth and development while maintaining the precise balance of nutrients needed to keep the body in a state of ketosis. Some families find the diet challenging to maintain long-term, as it restricts many common foods and requires precise meal planning and preparation.^[9]

Cannabis-Based Treatments

Over one-third of individuals with CDKL5 deficiency disorder have tried cannabis derivatives as part of their seizure management plan. These products typically contain cannabidiol (CBD), a compound found in cannabis plants that does not produce the “high” associated with marijuana but may have anti-seizure properties. Parents often turn to cannabis-based treatments after conventional medications have failed to adequately control their child’s seizures.^[9]

The response to cannabis derivatives varies from person to person, and research is still ongoing to determine which children are most likely to benefit. As with any treatment, families considering cannabis-based products should discuss the potential benefits and risks with their child’s healthcare team and ensure they use pharmaceutical-grade products with known concentrations of active ingredients.^[9]

Surgical Approaches for Severe Cases

When seizures remain uncontrolled despite multiple medication trials and dietary therapy, some families consider surgical options. These procedures are generally reserved for children with the most severe, treatment-resistant epilepsy. Surgical approaches used in CDD include vagus nerve stimulators (VNS), which are devices implanted under the skin that send regular electrical impulses to the brain through the vagus nerve in the neck; functional hemispherectomy, a major surgery that disconnects one hemisphere of the brain; and corpus callosotomy, which involves cutting the connection between the brain’s two hemispheres to prevent seizures from spreading.^[9]

Because these are complex procedures with significant risks, they require thorough evaluation by an epilepsy surgery team. The decision to pursue surgery depends on many factors, including the specific seizure patterns the child experiences, how much the seizures impact their quality of life, and whether the potential benefits outweigh the risks.^[9]

Managing Other Symptoms

Beyond seizures, children with CDKL5 deficiency disorder experience a range of other medical issues that require treatment. Sleep disturbances are common, and nearly one-third of individuals receive medication to help with sleep. These might include melatonin supplements or other sleep aids prescribed by their doctor. Good sleep is essential not only for the child’s health and development but also for the well-being of the entire family.^[9]

About 13 percent of individuals with CDD receive medications for behavioral dysregulation and movement disorders. Movement problems in CDD can include chorea (involuntary jerky movements), dystonia (sustained muscle contractions causing twisting movements), and stereotypical hand and leg movements (repetitive, purposeless motions). Medications used to address these symptoms depend on the specific type of movement disorder present.^[3][9]

Feeding difficulties are another major concern, as many children with CDD have trouble swallowing safely and may not be able to eat enough by mouth to support their growth. About 43 percent of individuals have gastrostomy tubes (G-tubes) surgically placed directly into their stomach to allow for safe nutrition delivery. This can prevent dangerous aspiration (when food or liquid enters the lungs) and ensure children receive adequate calories and nutrients.^[9]

Children may also need treatment for gastrointestinal issues like gastroesophageal reflux (when stomach acid flows back into the esophagus) and constipation. Medications to reduce stomach acid production or improve gut motility can help manage these problems. Working with a gastroenterologist is often essential to address the digestive challenges that come with CDD.^[2][15]

Orthopedic complications develop over time due to the low muscle tone many children experience. Scoliosis (curvature of the spine), hip dysplasia, and other skeletal problems may require physical therapy, bracing, or in some cases, corrective surgery. Regular monitoring by an orthopedic specialist helps catch these issues early when interventions can be most effective.^[2]

Treatment Approaches Being Tested in Clinical Trials

The First FDA-Approved Targeted Therapy

In March 2022, a major breakthrough occurred when the United States Food and Drug Administration (FDA) approved ganaxolone (brand name Ztalmy®) specifically for treating seizures associated with CDKL5 deficiency disorder in patients two years of age and older. This marked the first approved treatment specifically for seizures in CDD, representing a significant milestone for families affected by this condition.^[3][4][14]

Ganaxolone is a liquid anti-seizure medication that children take orally every day. It works differently from traditional anti-epileptic drugs. Ganaxolone is a neuroactive steroid that acts on GABA-A receptors in the brain. GABA (gamma-aminobutyric acid) is the brain’s main inhibitory neurotransmitter—it helps calm down excessive electrical activity. By enhancing GABA’s effects, ganaxolone can help reduce the occurrence of seizures.^[14][17]

The approval of ganaxolone came after the completion of the Marigold trial, a Phase III clinical study that specifically enrolled patients with CDKL5 deficiency disorder. Phase III trials are large, carefully controlled studies designed to compare a new treatment against current standard care or placebo (inactive treatment) to determine if the new approach is truly effective and safe. In the Marigold trial, ganaxolone significantly reduced the frequency of major motor seizures—the seizures involving obvious physical movements—in children with CDD.^[4][14]

Having an FDA-approved medication designed specifically for CDKL5 deficiency disorder represents a turning point. Before ganaxolone, all treatments for CDD seizures were used “off-label,” meaning doctors prescribed medications approved for other forms of epilepsy and hoped they would help children with CDD. Ganaxolone is the first drug that went through clinical trials enrolling only CDD patients, providing solid evidence of benefit in this specific population.^[3][4]

Understanding Clinical Trial Phases

When researchers develop new treatments, they must test them through several stages before they can become available to patients. Phase I trials are the first step, involving a small number of participants and focusing primarily on safety—determining what dose is safe and how the body processes the drug. Phase II trials involve more patients and begin to assess whether the treatment actually works, while still closely monitoring for side effects. Phase III trials, like the Marigold study for ganaxolone, are the largest and most rigorous, comparing the new treatment directly against current standards or placebo to definitively prove effectiveness.^[9]

This stepwise process ensures that only treatments proven both safe and effective reach patients. It also means that promising therapies currently in Phase I or Phase II may take several more years before they become widely available, as researchers gather the comprehensive data needed for regulatory approval.^[9]

Emerging Therapies and Future Directions

Beyond ganaxolone, researchers continue to explore additional treatments specifically designed for CDKL5 deficiency disorder. Some of these approaches aim to address the underlying problem—the shortage or dysfunction of the CDKL5 protein—rather than just managing symptoms. These include innovative strategies such as gene therapy, which would attempt to deliver a working copy of the CDKL5 gene to cells, and other molecular approaches targeting the specific pathways disrupted when CDKL5 is deficient.^[4]

While specific details about these experimental therapies are still emerging from ongoing research, the basic principle is to find ways to restore or compensate for the missing or malfunctioning CDKL5 protein. The CDKL5 protein acts as a kinase, an enzyme that modifies other proteins by adding phosphate groups to them. This process is essential for normal brain development and the proper functioning of nerve cells. When CDKL5 is absent or not working correctly, the cascade of events that depend on its activity go awry, leading to the symptoms of CDD.^[1][4]

Several research institutions and pharmaceutical companies are working on therapies that could potentially address this fundamental problem. Genetic therapies under investigation might use specially engineered viruses to deliver functional CDKL5 genes into brain cells. Other approaches might involve developing small molecule drugs that can compensate for the missing CDKL5 function or boost whatever residual CDKL5 activity remains in a person’s cells.^[4]

Clinical trials for these emerging therapies are being conducted at specialized centers, including CDKL5 Centers of Excellence in the United States and research institutions in Europe and other regions. Families interested in participating in clinical trials should discuss options with their child’s neurologist, who can determine if the child meets eligibility criteria for any ongoing studies. Participation in research not only offers access to potentially beneficial new treatments but also contributes to the scientific understanding of CDD that will help future patients.^[4][17]

The Role of Natural History Studies

One crucial type of research that supports the development of new treatments is the natural history study. These studies carefully track how CDKL5 deficiency disorder progresses over time in many individuals, documenting symptoms, developmental milestones, medical complications, and responses to various treatments. The International CDKL5 Disorder Database (ICDD) and studies conducted through the CDKL5 Centers of Excellence collect this vital information.^[4]

Natural history data serves multiple important purposes. It helps researchers understand the full spectrum of how CDD affects people, from those with milder symptoms to those most severely affected. This information is essential for designing clinical trials—researchers need to know what outcomes to measure, how much improvement would be clinically meaningful, and what to expect from the natural course of the disease. Natural history studies also help identify which symptoms are most burdensome to patients and families, guiding researchers toward the most pressing treatment needs.^[4]

Families can contribute to this important research by enrolling in registries and participating in natural history studies, even if they’re not eligible for trials of experimental medications. The data collected from every patient helps build the foundation for future breakthroughs.^[4]

Most Common Treatment Methods

• Anti-seizure Medications
  • Broad-spectrum anti-epileptic drugs are prescribed in over 50 percent of patients to reduce seizure frequency and severity
  • Response varies significantly, with sustained three-month response achieved in only 5 to 36 percent of those treated
  • Multiple medications are often tried in combination to find the most effective regimen for each individual
  • Ganaxolone (Ztalmy®) is the first FDA-approved medication specifically for seizures associated with CDD in patients two years and older
• Ketogenic Diet
  • Used in approximately 50 percent of individuals with CDD to help control seizures
  • A specialized high-fat, low-carbohydrate eating plan that shifts the body’s energy metabolism
  • Requires careful supervision by a dietitian and medical team to ensure proper nutrition
  • May reduce seizure activity in some children through mechanisms that are not fully understood
• Cannabis-Based Treatments
  • Tried in over one-third of individuals with CDKL5 deficiency disorder
  • Products typically contain cannabidiol (CBD), which may have anti-seizure properties
  • Often considered after conventional medications have not adequately controlled seizures
  • Response varies among individuals and requires pharmaceutical-grade products with known concentrations
• Surgical Interventions
  • Vagus nerve stimulators (VNS) are implanted devices that send electrical impulses to the brain
  • Functional hemispherectomy disconnects one hemisphere of the brain in severe cases
  • Corpus callosotomy cuts the connection between brain hemispheres to prevent seizure spread
  • Reserved for the most treatment-resistant epilepsy after careful evaluation by specialists
• Nutritional Support
  • Gastrostomy tubes (G-tubes) are placed in about 43 percent of individuals to provide safe nutrition
  • Prevents dangerous aspiration and ensures adequate calorie and nutrient intake
  • Allows for medication administration when oral intake is difficult
  • Dietitians work with families to optimize nutrition for growth and development
• Symptomatic Medications
  • Nearly one-third of individuals receive medications for sleep disturbances, including melatonin or prescribed sleep aids
  • About 13 percent take medications for behavioral issues and movement disorders
  • Medications for gastroesophageal reflux and constipation help manage digestive problems
  • Treatment plans are individualized based on each person’s specific symptom profile
• Physical and Supportive Therapies
  • Physical therapy addresses motor delays and helps maintain muscle strength and flexibility
  • Occupational therapy works on fine motor skills and daily living activities
  • Speech-language pathologists assist with communication and feeding issues
  • Orthopedic care monitors and treats complications like scoliosis and hip dysplasia
• Clinical Trial Therapies
  • Ganaxolone completed Phase III trials (Marigold study) and received FDA approval in 2022
  • Gene therapy approaches are under investigation to deliver functional CDKL5 genes
  • Small molecule drugs being developed to compensate for missing CDKL5 function
  • Trials are conducted at specialized centers including CDKL5 Centers of Excellence